# Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer

> **NCT00203411** · PHASE2 · COMPLETED · sponsor: **Translational Oncology Research International** · enrollment: 45 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Capecitabine (Xeloda)
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00203411
- **Lead sponsor:** Translational Oncology Research International
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-03
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2017-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00203411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00203411, "Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00203411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*